Clinical trials: Multiple System Atrophy, open to volunteers
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study.
- Trial name
- SPRITE (NCT06765733)
- Testing
- Aleeto
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
AB-1005 Long-Term Follow-up Study
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005.
- Trial name
- NCT07081841
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- AskBio Inc
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
- Trial name
- NCT07617012
- Testing
- XS411CN Cell Injection
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Parkinson Disease, Dementia With Lewy Bodies
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of [18F]-MFBG PET in assessing cardiac innervation, comparing it with [123I]-MIBG SPECT The study's primary focus is on…
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
- Trial name
- NCT06120049
- Testing
- [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT
- Where
- 2 sites in Belgium
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Sarcopenia in Elderly
A Study of PLH-2301 in Subjects With Sarcopenia
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.
- Trial name
- PLH-2301_P2 (NCT07390552)
- Testing
- PLH-2301
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Pluto Inc.
Parkinson's Disease, Progressive Supranuclear Palsy(PSP)
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.
- Conditions
- Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
- Trial name
- NCT07392411
- Testing
- video recording
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Polyneuropathy, Alpha-Synucleinopathy
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System
Description of a method to detect Parkinson's disease or Parkinson's-like disease at an early stage (Prodromal Parkinson's Disease) where damage is still confined to the peripheral nervous system damage.
- Conditions
- Polyneuropathy, Alpha-Synucleinopathy, Lewy Body Disease, Parkinson Disease (PD)
- Trial name
- Prompark (NCT06745011)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Orthostatic; Hypotension, Neurogenic, Autonomic Failure
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension.
- Conditions
- Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT04782830
- Testing
- Accelerometer, Midodrine or atomoxetine pill
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease and Related Dementias, Cognition
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function…
- Conditions
- Alzheimer Disease and Related Dementias, Cognition, Mobility Disability
- Trial name
- TDCS4MCR (NCT06821568)
- Testing
- Personalized Transcranial Direct Current Stimulation (tDCS)
- Where
- 2 sites in United States, Israel
- Volunteers
- 128 people
- Sponsor
- Hebrew SeniorLife
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma.
- Conditions
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease, Cystic Fibrosis, Fragile X Syndrome
- Trial name
- DANNIgene (NCT06147414)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple System Atrophy
Comprehensive Swallowing Rehabilitation in Patients With MSA
The purpose of this study is to investigate the effect of comprehensive swallowing rehabilitation in patients with multiple system atrophy.
- Trial name
- NCT04782284
- Testing
- Comprehensive swallowing rehabilitation, Swallowing education
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Seoul National University Hospital
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Sudden Cardiac Death
Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death
This study is designed as a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death), which enrolls high-risk…
- Trial name
- SMART-SCD (NCT07476456)
- Where
- China
- Volunteers
- 421 people
- Sponsor
- China National Center for Cardiovascular Diseases
Spinal Muscular Atrophy (SMA)
Advanced Multi-omics and -System Approaches to Identify Novel Biomarkers for SMA
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to motor neuron degeneration and progressive muscle atrophy.
- Trial name
- MOSAiC-SMA (NCT07883655)
- Where
- 3 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituto Giannina Gaslini
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Multiple System Atrophy, Parkinsons Disease
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's…
- Trial name
- LEAP (NCT06683365)
- Testing
- Sural Nerve Graft to the Substantia Nigra
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Craig van Horne, MD, PhD
Eye Diseases Hereditary, Retinal Disease
Inherited Retinal Degenerative Disease Registry
The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation.
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome
- Trial name
- MRTR (NCT02435940)
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Foundation Fighting Blindness
Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic
Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury
The study aims to explore how cardiovascular function changes in the first year after a spinal cord injury, and to see how different treatments, like spinal stimulation through the skin (transcutaneous spinal stimulation), affect…
- Conditions
- Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic, Cardiovascular, Transcutaneous Spinal Stimulation
- Trial name
- NCT06841198
- Testing
- spinal cord transcutaneous stimulation, Ice testing
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation